CD274 and neoplasm: PD-L1 and tumour mutation burden (TMB) detection are used to screen the potential beneficiaries of immune checkpoint inhibitors for advanced NSCLC in clinical practice; however, the predictive efficacy of PD-L1 and TMB as pretreatment markers remains controversial [10, 11, 17, 18].